AstraZeneca To Shut Indian API Site
This article was originally published in PharmAsia News
AstraZeneca is shuttering its Indian active pharmaceutical ingredient unit in Yelahanka, Bangalore in a move the UK-based firm says was triggered by low export demand for the key product made there.
You may also be interested in...
AstraZeneca expects to invest $90m over five years to shore up its footprint in India – a market where the Anglo-Swedish major has introduced a string of new products but has also had a fair share of challenges.
A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.
Glenmark hopes complex and respiratory products including a potential filing for generic Flovent pMDI can restore some lost sheen of its US business going forward, but a compliance comeback for its Monroe site may be pivotal to deliver material gains.